Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.

@article{Minckwitz2014NeoadjuvantCI,
  title={Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.},
  author={Gunter von Minckwitz and Andreas Schneeweiss and Sibylle Loibl and Christoph Salat and Carsten Denkert and Mahdi Rezai and Jens Uwe Blohmer and Christian Jackisch and Stefan Paepke and Bruno E. Gerber and Dirk Michael Zahm and Sherko K{\"u}mmel and Holger Eidtmann and Peter Klare and Jens Huober and Serban Dan Costa and Hans Tesch and Claus Hanusch and Joern Hilfrich and Fariba Khandan and Peter A. Fasching and Bruno Valentin Sinn and K. A. Engels and Keyur Mehta and Valentina Nekljudova and Michael Untch},
  journal={The Lancet. Oncology},
  year={2014},
  volume={15 7},
  pages={
          747-56
        }
}
BACKGROUND Preclinical data suggest that triple-negative breast cancers are sensitive to interstrand crosslinking agents, and that synergy may exist for the combination of a taxane, trastuzumab, and a platinum salt for HER2-positive breast cancer. We therefore aimed to assess the efficacy of the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive breast cancer. METHODS Patients with previously untreated, non-metastatic, stage II-III, triple-negative breast… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 190 CITATIONS

FILTER CITATIONS BY YEAR

2014
2019

CITATION STATISTICS

  • 15 Highly Influenced Citations

  • Averaged 44 Citations per year over the last 3 years

Similar Papers

Loading similar papers…